Experimental HCV Drugs
Experimental HCV Drugs
EASL 2016: Adolescents with Hepatitis C Achieve High Cure Rates with Sofosbuvir/Ledipasvir
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 22 April 2016 00:00
- Written by Liz Highleyman
Sofosbuvir/ledipasvir (Harvoni) was well-tolerated and led to sustained virological response in 97% of adolescents (age 12-17) with chronic hepatitis C, with high cure rates regardless of prior treatment experience or presence of liver cirrhosis, according to a report presented at the 2016 EASL International Liver Congress in Barcelona.
EASL 2016: Novel Therapy RG-101 Plus Antivirals Could Cure Hepatitis C in 4 Weeks
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 18 April 2016 00:00
- Written by Liz Highleyman
Two injections of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, combined with direct-acting antiviral agents (DAAs) taken for just 4 weeks led to 12-week post-treatment sustained response in 97% of chronic hepatitis C patients, according to study results presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 14 April 2016 00:00
- Written by Liz Highleyman
A triple combination of Gilead Sciences' sofosbuvir, velpatasvir, and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior direct-acting antivirals (DAAs), according to 2 presentations at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.
EASL 2016: $300 Hepatitis C Combination with Ravidasvir to Enter Clinical Trials
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 April 2016 00:00
- Written by Keith Alcorn
The Drugs for Neglected Diseases Initiative (DNDi) is launching clinical trials in Thailand and Malaysia to test a combination of sofosbuvir and ravidasvir, an NS5A inhibitor, in at least 800 people with all genotypes of hepatitis C virus (HCV). The combination, manufactured by Egyptian company Pharco, could be made available for $300 for a course of treatment if it proves safe and effective, DNDi executive director Bernard Pécoul announced ahead of the 2016 EASL International Liver Congress this week in Barcelona. The studies will aim to test an affordable pangenotypic combination and to provide data for regulatory submission.
CROI 2016: Ravidasvir Plus Sofosbuvir Demonstrates High Cure Rate for HCV Genotype 4
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 04 March 2016 00:00
- Written by Liz Highleyman
Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95% to 100% of people with hepatitis C virus (HCV) genotype 4, the most common type in Egypt, according to findings from the Pyramid 1 study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last week in Boston.
More Articles...
- Coverage of the 2016 Conference on Retroviruses and Opportunistic Infections
- Daclatasvir Plus Asunaprevir Cures Most Genotype 1b Chinese Hepatitis C Patients
- AASLD 2015: MiR-122 Inhibitor RG-101 Suppresses Hepatitis C Virus with Single Dose
- FDA Approves Zepatier (Grazoprevir/Elbasvir) for Hepatitis C Genotypes 1 and 4
Web Design and Development by